Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
trading_symbol | registrant_name | time | price | change | percentage_change |
---|---|---|---|---|---|
ELAN | Elanco Animal Health Inc | 2025-10-16 18:35:43 | 20.12 | -0.4 | -1.95 |
trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ELAN | 0001739104 | Elanco Animal Health Inc | US28414H1032 | 549300SHPNDCE059M934 | 825497352 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | — | 2500 INNOVATION WAY | GREENFIELD | IN | 46140 | UNITED STATES | US | 877-352-6261 | 2500 INNOVATION WAY, GREENFIELD, IN, 46140 | 2500 INNOVATION WAY, GREENFIELD, IN, 46140 | — | Pharmaceutical (animal) | 1954 | Jeff Simmons | 10,200 | http://elanco.com | 7,100,000,000 | 496,646,312 | 496,813,702 | Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world. | 2025-10-10 19:49:23 |
Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
---|---|---|---|---|---|---|
2024 | 7,100,000,000 | 2,200,000,000 | 44.898 | 494,613,940 | 1,643,929 | 0.3335 |
2023 | 4,900,000,000 | -4,400,000,000 | -47.3118 | 492,970,011 | 1,426,510 | 0.2902 |
2022 | 9,300,000,000 | -7,100,000,000 | -43.2927 | 491,543,501 | 18,356,749 | 3.8794 |
Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
---|---|---|---|---|---|---|---|---|
Ellen De Brabander | Executive Vice President | 2024 | 753,048 | 0 | 2,031,537 | 581,730 | 37,115 | 3,913,932 |
Ramiro Cabral | President, Executive Vice President | 2024 | 620,000 | 0 | 1,361,268 | 478,950 | 28,501 | 2,942,471 |
Jeffrey Simmons | CEO, President | 2024 | 1,200,000 | 0 | 9,000,027 | 1,606,800 | 26,871 | 14,833,704 |
Todd Young | Chief Financial Officer, Executive Vice President | 2024 | 694,000 | 0 | 2,111,279 | 571,856 | 28,471 | 4,109,361 |
Timothy Bettington | Executive Vice President | 2024 | 642,000 | 0 | 1,050,029 | 462,882 | 28,471 | 2,533,389 |
Fiscal Year | Employee Count |
---|---|
2024 | 9,000 |
2023 | 9,300 |
2022 | 9,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Revenue | 4,439,000,000 | 4,417,000,000 | 4,411,000,000 |
Cost Of Revenue | 2,003,000,000 | 1,931,000,000 | 1,913,000,000 |
Gross Profit | 2,436,000,000 | — | — |
Research And Development Expenses | 344,000,000 | 327,000,000 | 321,000,000 |
General And Administrative Expenses | 1,314,000,000 | 1,285,000,000 | 1,265,000,000 |
Operating Expenses | 3,951,000,000 | 5,612,000,000 | 4,483,000,000 |
Operating Income | — | — | — |
Net Income | 338,000,000 | -1,231,000,000 | -78,000,000 |
Earnings Per Share Basic | 0.68 | -2.5 | -0.16 |
Earnings Per Share Diluted | 0.68 | -2.5 | -0.16 |
Weighted Average Shares Outstanding Basic | 494,000,000 | 492,300,000 | 488,300,000 |
Weighted Average Shares Outstanding Diluted | 497,300,000 | 492,300,000 | 488,300,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Cash And Cash Equivalents | 468,000,000 | 352,000,000 | 345,000,000 |
Marketable Securities Current | — | — | — |
Accounts Receivable | 805,000,000 | 842,000,000 | 797,000,000 |
Inventories | 1,574,000,000 | 1,735,000,000 | 1,538,000,000 |
Non Trade Receivables | 121,000,000 | 149,000,000 | 180,000,000 |
Other Assets Current | — | — | — |
Total Assets Current | 3,215,000,000 | 3,407,000,000 | 3,279,000,000 |
Marketable Securities Non Current | — | — | — |
Property Plant And Equipment | 993,000,000 | 1,026,000,000 | 999,000,000 |
Other Assets Non Current | 311,000,000 | 341,000,000 | 378,000,000 |
Total Assets Non Current | 9,399,000,000 | 10,955,000,000 | 12,212,000,000 |
Total Assets | 12,614,000,000 | 14,362,000,000 | 15,491,000,000 |
Accounts Payable | 296,000,000 | 270,000,000 | 390,000,000 |
Deferred Revenue | 332,000,000 | 367,000,000 | 324,000,000 |
Short Term Debt | 44,000,000 | 38,000,000 | 388,000,000 |
Other Liabilities Current | 466,000,000 | 409,000,000 | 454,000,000 |
Total Liabilities Current | 1,315,000,000 | 1,241,000,000 | 1,702,000,000 |
Long Term Debt | 4,321,000,000 | 5,774,000,000 | 5,836,000,000 |
Other Liabilities Non Current | 302,000,000 | 411,000,000 | 229,000,000 |
Total Liabilities Non Current | 5,203,000,000 | 6,898,000,000 | 6,500,000,000 |
Total Liabilities | 6,518,000,000 | 8,139,000,000 | 8,202,000,000 |
Common Stock | 0 | 0 | 0 |
Retained Earnings | -1,950,000,000 | -2,288,000,000 | -1,057,000,000 |
Accumulated Other Comprehensive Income | -771,000,000 | -266,000,000 | -392,000,000 |
Total Shareholders Equity | 6,096,000,000 | 6,223,000,000 | 7,289,000,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Depreciation And Amortization | 662,000,000 | 694,000,000 | 682,000,000 |
Share Based Compensation Expense | 55,000,000 | 46,000,000 | 59,000,000 |
Other Non Cash Income Expense | — | — | — |
Change In Accounts Receivable | -12,000,000 | 40,000,000 | -14,000,000 |
Change In Inventories | -44,000,000 | 160,000,000 | 269,000,000 |
Change In Non Trade Receivables | — | — | — |
Change In Other Assets | -11,000,000 | 6,000,000 | 109,000,000 |
Change In Accounts Payable | — | — | — |
Change In Other Liabilities | — | 0 | 0 |
Cash From Operating Activities | 541,000,000 | 271,000,000 | 452,000,000 |
Purchases Of Marketable Securities | — | — | — |
Sales Of Marketable Securities | — | — | — |
Acquisition Of Property Plant And Equipment | 147,000,000 | 140,000,000 | 137,000,000 |
Acquisition Of Business | 41,000,000 | 19,000,000 | 0 |
Other Investing Activities | 0 | -4,000,000 | 8,000,000 |
Cash From Investing Activities | 1,158,000,000 | -169,000,000 | -179,000,000 |
Tax Withholding For Share Based Compensation | — | — | — |
Payments Of Dividends | — | — | — |
Issuance Of Common Stock | — | 0 | 0 |
Repurchase Of Common Stock | — | — | — |
Issuance Of Long Term Debt | 350,000,000 | — | 425,000,000 |
Repayment Of Long Term Debt | 250,000,000 | 150,000,000 | 813,000,000 |
Other Financing Activities | -17,000,000 | -6,000,000 | -16,000,000 |
Cash From Financing Activities | -1,492,000,000 | -83,000,000 | -549,000,000 |
Change In Cash | 116,000,000 | 7,000,000 | -293,000,000 |
Cash At End Of Period | 468,000,000 | 352,000,000 | 345,000,000 |
Income Taxes Paid | 140,000,000 | 95,000,000 | 93,000,000 |
Interest Paid | 296,000,000 | 379,000,000 | 266,000,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Earnings Per Share | 0.68 | -2.5 | -0.16 |
Price To Earnings Ratio | 17.8088 | -5.96 | -76.375 |
Earnings Growth Rate | -127.2 | 1,462.5 | -83.5052 |
Price Earnings To Growth Ratio | -0.14 | -0.0041 | 0.9146 |
Book Value Per Share | 12.3401 | 12.6407 | 14.9273 |
Price To Book Ratio | 0.9814 | 1.1787 | 0.8186 |
Ebitda | 1,140,000,000 | -165,000,000 | 938,000,000 |
Enterprise Value | 9,879,340,000 | 12,795,270,000 | 11,846,026,000 |
Dividend Yield | — | — | — |
Dividend Payout Ratio | — | — | — |
Debt To Equity Ratio | 0.716 | 0.934 | 0.8539 |
Capital Expenditures | 629,000,000 | 721,000,000 | 620,000,000 |
Free Cash Flow | -88,000,000 | -450,000,000 | -168,000,000 |
Return On Equity | 0.0554 | -0.1978 | -0.0107 |
One Year Beta | 1.0337 | 1.9487 | 1.0231 |
Three Year Beta | 1.1999 | 1.1418 | 1.0134 |
Five Year Beta | 1.0865 | 1.0731 | 0.9689 |
Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
---|---|---|---|---|---|
Simmons Jeffrey N | Director, PRESIDENT, CEO AND DIRECTOR | 2025-10-03 | 134 | A | 17,970 |
Modi Rajeev A. | — | 2025-10-03 | 68 | A | 7,033 |
VanHimbergen Robert M | EVP and CFO | 2025-10-01 | 109,857 | A | 109,857 |
VanHimbergen Robert M | EVP and CFO | 2025-10-01 | 53,869 | A | 53,869 |
Anand Kapila K | Director | 2025-09-30 | 428 | A | 8,513 |
Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
---|---|---|---|---|---|---|
Daniel S Sullivan | Senator | 2023-07-26 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
Daniel S Sullivan | Senator | 2022-12-21 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
---|---|---|---|---|---|---|
Valerie Hoyle | 2025-10-10 | OR04 | Sale | 2025-09-23 | Spouse | $1,001 - $15,000 |
Daniel Goldman | 2023-04-17 | NY10 | Sale (Partial) | 2023-03-06 | — | $1,001 - $15,000 |
Susie Lee | 2022-12-29 | NV03 | Sale | 2022-11-30 | Joint | $1,001 - $15,000 |
Alan S. Lowenthal | 2019-09-01 | CA47 | Sale | 2019-08-20 | Spouse | $15,001 - $50,000 |
Alan S. Lowenthal | 2019-09-01 | CA47 | Sale | 2019-08-20 | Spouse | $1,001 - $15,000 |
Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
---|---|---|---|---|
180 WEALTH ADVISORS, LLC | 2025-09-30 | 625,266 | 31,046 | 20.14 |
Blue Trust, Inc. | 2025-09-30 | 79,271 | 3,936 | 20.14 |
CWM, LLC | 2025-09-30 | 196,000 | 9,722 | 20.1605 |
Pacer Advisors, Inc. | 2025-09-30 | 1,713,652 | 85,087 | 20.14 |
HARBOR CAPITAL ADVISORS, INC. | 2025-09-30 | 3,083,000 | 153,063 | 20.142 |
Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
---|---|---|---|---|---|---|
TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Mid Cap Fund | CFMCX | 12,769 | 234,311.15 | 0.0235 |
TIAA-CREF FUNDS | 2025-07-31 | Class I | TEIHX | 406,143 | 5,556,036.24 | 0.0103 |
TIAA-CREF FUNDS | 2025-07-31 | Premier Class | TCEPX | 406,143 | 5,556,036.24 | 0.0103 |
TIAA-CREF FUNDS | 2025-07-31 | Class A | TINRX | 406,143 | 5,556,036.24 | 0.0103 |
TIAA-CREF FUNDS | 2025-07-31 | Retirement Class | TIQRX | 406,143 | 5,556,036.24 | 0.0103 |